Citi slashes Human Genome target on slow Benlysta sales

Doctors aren't flocking to Benlysta, the new lupus treatment developed by Human Genome Sciences ($HGSI) and marketed in partnership with GlaxoSmithKline ($GSK), Citi analyst Dr. Yaron Werber says in a new note to investors. As the Associated Press reports, Werber cut his price target on HGS stock to $15 from $26 on the slow uptake. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.